CN105431163A - 索布替罗用于治疗髓鞘形成疾病 - Google Patents

索布替罗用于治疗髓鞘形成疾病 Download PDF

Info

Publication number
CN105431163A
CN105431163A CN201480038129.XA CN201480038129A CN105431163A CN 105431163 A CN105431163 A CN 105431163A CN 201480038129 A CN201480038129 A CN 201480038129A CN 105431163 A CN105431163 A CN 105431163A
Authority
CN
China
Prior art keywords
disease
patient
sieve
pharmacy
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480038129.XA
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·S·斯坎伦
梅雷迪思·哈特利
安德鲁·普拉切克
马可·瑞纪
丹尼斯·布尔德特
盖尔·卡拉齐
普利亚·乔杜里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
U S GOVERNMENT AS REPRESENTED
Oregon Health and Science University
Original Assignee
U S GOVERNMENT AS REPRESENTED
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S GOVERNMENT AS REPRESENTED, Oregon Health and Science University filed Critical U S GOVERNMENT AS REPRESENTED
Publication of CN105431163A publication Critical patent/CN105431163A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201480038129.XA 2013-05-03 2014-02-05 索布替罗用于治疗髓鞘形成疾病 Pending CN105431163A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
US61/819,467 2013-05-03
USPCT/US2013/0053640 2013-08-05
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Publications (1)

Publication Number Publication Date
CN105431163A true CN105431163A (zh) 2016-03-23

Family

ID=51843844

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480038129.XA Pending CN105431163A (zh) 2013-05-03 2014-02-05 索布替罗用于治疗髓鞘形成疾病

Country Status (12)

Country Link
US (3) US10226438B2 (https=)
EP (1) EP2991670B8 (https=)
JP (4) JP2016517883A (https=)
CN (1) CN105431163A (https=)
AU (1) AU2014260468A1 (https=)
BR (1) BR112015027682A2 (https=)
CA (1) CA2911309A1 (https=)
ES (1) ES2745532T3 (https=)
MX (2) MX379043B (https=)
RU (1) RU2015151216A (https=)
SG (2) SG10201709090UA (https=)
WO (2) WO2014178892A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475121A (zh) * 2016-05-18 2019-03-15 俄勒冈健康科学大学 苏比替罗衍生物
CN109843849A (zh) * 2016-08-12 2019-06-04 俄勒冈健康科学大学 酰胺化合物、其药物组合物及其使用方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
CA2946422C (en) 2014-04-30 2019-03-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
JP6342575B2 (ja) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
CA3003589C (en) * 2015-10-29 2021-12-07 The Johns Hopkins University Dendrimer compositions and methods for treatment of peroxisomal disorders and leukodystrophies
BR112018071559B1 (pt) * 2016-04-22 2024-02-06 Viking Therapeutics, Inc Uso de um agonista de receptor beta de hormônios da tireoide para o tratamento de adrenoleucodistrofia ligada ao x
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
IL270169B2 (en) 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer preparations for use in angiography
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
EP3644983B1 (en) 2017-06-29 2023-10-25 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
AU2018302641B2 (en) 2017-07-18 2024-12-19 Keio University Anti-bacterial composition against Th1 cell-inducing bacteria
US11918657B2 (en) 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020180624A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
US12466781B2 (en) 2019-11-29 2025-11-11 Autobahn Therapeutics, Inc. Thyromimetics
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
WO2021257851A1 (en) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
US12590072B2 (en) 2020-06-17 2026-03-31 Autobahn Therapeutics, Inc. Thyromimetics
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600450A (zh) * 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
CN101610774A (zh) * 2006-11-03 2009-12-23 萨斯喀彻温大学 治疗脱髓鞘疾病的方法
CN101848712A (zh) * 2007-07-11 2010-09-29 美迪诺亚公司 用异丁地特治疗渐进性神经变性疾病

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US6236946B1 (en) 1995-12-13 2001-05-22 Thomas S. Scanlan Nuclear receptor ligands and ligand binding domains
WO1998007435A1 (en) 1996-08-20 1998-02-26 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
CA2335551C (en) 1998-06-30 2009-03-03 The Regents Of The University Of California Thyroid hormone analogues and methods for their preparation
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CA2539288C (en) * 2003-09-15 2015-05-12 Shaker A. Mousa Thyroid hormone analogs and methods of use
WO2006012015A2 (en) * 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
CN101102758B (zh) * 2004-09-15 2011-11-16 奥德威研究院 促进血管新生的甲状腺激素类似物
WO2006105205A1 (en) 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION
TW201221505A (en) * 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
PT2651357T (pt) 2010-12-16 2020-06-17 Sunovion Pharmaceuticals Inc Películas sublinguais
JP6060268B2 (ja) * 2012-10-25 2017-01-11 ボルボ トラック コーポレイション 車両用電子制御エアブレーキシステム、そのようなシステムを備える車両及びそのようなシステムを制御する方法
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600450A (zh) * 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
CN101610774A (zh) * 2006-11-03 2009-12-23 萨斯喀彻温大学 治疗脱髓鞘疾病的方法
CN101848712A (zh) * 2007-07-11 2010-09-29 美迪诺亚公司 用异丁地特治疗渐进性神经变性疾病

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EMMANUELLE C.GENIN ET.AL: "Induction of the adrenoleukodystrophy-related gene(ABCD2) by thyromimetics", 《JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475121A (zh) * 2016-05-18 2019-03-15 俄勒冈健康科学大学 苏比替罗衍生物
CN109475121B (zh) * 2016-05-18 2021-06-25 俄勒冈健康科学大学 苏比替罗衍生物
CN113277958A (zh) * 2016-05-18 2021-08-20 俄勒冈健康科学大学 苏比替罗衍生物
CN109843849A (zh) * 2016-08-12 2019-06-04 俄勒冈健康科学大学 酰胺化合物、其药物组合物及其使用方法
US11325886B2 (en) 2016-08-12 2022-05-10 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
CN109843849B (zh) * 2016-08-12 2023-09-22 俄勒冈健康科学大学 酰胺化合物、其药物组合物及其使用方法

Also Published As

Publication number Publication date
JP6360552B6 (ja) 2018-08-15
US10226438B2 (en) 2019-03-12
SG10201709090UA (en) 2017-12-28
AU2014260468A1 (en) 2015-11-19
JP6360552B2 (ja) 2018-07-18
HK1222552A1 (en) 2017-07-07
JP2018141024A (ja) 2018-09-13
RU2015151216A (ru) 2017-06-08
MX379043B (es) 2025-03-10
JP2018162321A (ja) 2018-10-18
US20190175531A1 (en) 2019-06-13
WO2014178892A1 (en) 2014-11-06
EP2991670A4 (en) 2017-01-18
US20200405669A1 (en) 2020-12-31
JP2016517884A (ja) 2016-06-20
EP2991670B1 (en) 2019-07-03
EP2991670A1 (en) 2016-03-09
BR112015027682A2 (pt) 2017-08-29
CA2911309A1 (en) 2014-11-06
US11510887B2 (en) 2022-11-29
SG11201509012QA (en) 2015-11-27
WO2014178931A1 (en) 2014-11-06
MX2015015228A (es) 2016-10-03
JP2016517883A (ja) 2016-06-20
WO2014178892A8 (en) 2015-12-17
EP2991670B8 (en) 2019-09-11
US20160081955A1 (en) 2016-03-24
WO2014178931A8 (en) 2015-11-26
ES2745532T3 (es) 2020-03-02
MX2021000538A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
CN105431163A (zh) 索布替罗用于治疗髓鞘形成疾病
Zhu et al. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study
Tateishi Subacute myelo‐optico‐neuropathy: clioquinol intoxication in humans and animals
US20030114415A1 (en) Compositions and methods for treating and preventing memory impairment using citicoline
US12594255B2 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
Zohar et al. PKC activator therapeutic for mild traumatic brain injury in mice
Kopruszinski et al. Vitamin B complex attenuated heat hyperalgesia following infraorbital nerve constriction in rats and reduced capsaicin in vivo and in vitro effects
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
EP3461479A1 (en) Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
JP2011121976A (ja) 線維筋痛症に伴う口腔乾燥症を改善するための線維筋痛症に伴う口腔乾燥症改善用医薬組成物
CN103908567B (zh) 一种用于治疗糖尿病痛性神经病变的复方制剂及其应用
US20240058308A1 (en) Treatment and prevention of dry macular degeneration
CN107281203A (zh) 娑罗子提取物在制备防治老年痴呆药物中的应用
JP2008044879A (ja) ラクトフェリンを含有する医薬組成物ならびに加工食品
CA3026152C (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
CN107281206A (zh) 黑升麻苷在制备防治老年性痴呆药物中的应用
CN118302163A (zh) α-1062用于治疗创伤性脑损伤
US20140080908A1 (en) Compositions and methods for improving or preventing depression-like symptoms
HK1222552B (en) Sobetirome in the treatment of myelination diseases
Matray-Devoti Serotonergic and environmental manipulation of alcohol-induced aggression in mice
HK40021759B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
JP2016102068A (ja) 鯨筋肉抽出物からなる中長期記憶障害予防改善剤
HK1155659B (en) Pharmaceutical composition for treatment of fibromyalgia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160323